Trial Profile
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ZEN 3694 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Zenith Epigenetics
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2016 Status changed from not yet recruiting to recruiting.